AMY MEUSBORN: Open Payments
NPI 1962630871 · MANHATTAN, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$643 in 31 payments from 11 companies in 2025. Trend: 2023 $840 · 2024 $783 · 2025 $643
Food & beverage: $565Education: $78
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $178 |
| ABBVIE INC. | 11 | $136 |
| Sumitomo Pharma America, Inc. | 2 | $99 |
| PFIZER INC. | 3 | $73 |
| 180 Medical, Inc. | 2 | $52 |
| UROGEN PHARMA, INC. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Teleflex LLC | 1 | $19 |
| Boston Scientific Corporation | 1 | $15 |
| TOLMAR, INC. | 1 | $14 |
Products named: ERLEADA, GEMTESA, LUPRON DEPOT, XTANDI, BOTOX, EOHILIA, UROLIFT, RYBREVANT.
Industry payments across KS — which companies pay providers there.
